Physician profile
Dewitt C Alfred
NPI 1659313955
$1,154.10
in general payments reported to CMS, 2019-2025
10 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $83.61 · 2021: $83.59 · 2022: $96.90 · 2023: $100 · 2024: $121 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $370.42 | 2019-2025 | Lybalvi |
| Lundbeck LLC | $158.20 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $151.90 | 2019-2025 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.85 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $81.75 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $80.29 | 2019-2024 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $66.76 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $50.15 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $28.88 | 2022 | |
| Abbvie INC. | $25.90 | 2023 | Vraylar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dewitt Alfred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.